Provider FAQs for NeXT Dx™ Test
Provider FAQs for NeXT Dx™ Test This document covers Provider FAQs and cancer genes of clinical importance covered by the Personalis NeXT Dx™ Test.
25 Jan, 2021
8 Oct, 2020
NeXT Dx™ Test Gene List
NeXT Dx™ Test Gene List Cancer Genes of Clinical Importance Single nucleotide variants, small insertions and deletions, copy number alterations, and gene fusions involving the genes in the NeXT Dx Test Gene List may be reported in the test. Genes for which copy number alteration is assessed are indicated by [...]
6 Oct, 2020
SHERPA™ Bioinformatics Engine
SHERPA™ Bioinformatics Engine Systematic HLA Epitope Ranking Pan Algorithm Technologies for neoantigen discovery are critical for developing personalized cancer vaccines and neoantigen-based biomarkers. Precision neoantigen discovery entails the comprehensive detection of tumor-specific genomic variants and accurate prediction of MHC presentation of epitopes originating from such variants. The ImmunoID NeXT [...]
2 Aug, 2020
NeXT Liquid Biopsy
NeXT Liquid Biopsy™ It’s Time to Think About More. High-Performance Whole Exome Sequencing from Plasma. Highlights Comprehensively profile the tumor, exome-wide Combined with ImmunoID NeXT™, assess tumor heterogeneity, monitor response to therapy, and interrogate mechanisms of resistance Profile with ImmunoID NeXT, Monitor with NeXT Liquid Biopsy Leverage somatic variant [...]
29 Jan, 2020
Personalis NeXT Dx™ Test Data Sheet
Personalis NeXT Dx™ Test Increasingly, oncologists and pathologists are utilizing information on genomic alterations in solid tumors, such as lung, colon, breast, melanoma, and prostate cancers, to help guide and optimize therapeutic options for patients including enrolling into cancer clinical trials. The Personalis NeXT Dx™ Test provides clinicians with a comprehensive [...]
10 Jan, 2019
RepertoireID data sheet
RepertoireID An analytical module of the ImmunoID NeXT Platform Comprehensive Profiling of the TCR Repertoire RepertoireID, an analytics module of the ImmunoID NeXT Platform, enables the detection and analysis of the top TCRα and TCRβ clonotypes in the TCR repertoire found in the tumor microenvironment (TME) of patients’ tumors. [...]
5 Nov, 2018
NeoantigenID Data Sheet – An analytical module of the ImmunoID NeXT Platform
NeoantigenID™ An analytical module of the ImmunoID NeXT PlatformTM Comprehensive Identification of Putative Neoantigens Neoantigens are mutated peptides that are expressed by tumor cells, but not by normal tissue. As a result, they can be recognized as foreign antigens by cells of the immune system — making them promising [...]
5 Nov, 2018
ImmunogenomicsID Data Sheet – An analytical module of the ImmunoID NeXT Platform
ImmunogenomicsID An analytical module of the ImmunoID NeXT PlatformTM Comprehensive Immunogenomic Characterization ImmunogenomicsIDTM, an analytical module of the ImmunoID NeXT Platform, characterizes critical areas of tumor and immune biology such as the antigen processing machinery (APM), human leukocyte antigens (HLA), checkpoint modulation, tumor escape mechanisms, the adaptive and innate [...]
21 Mar, 2018
NeoantigenID
NeoantigenID™ Comprehensive identification of putative neoantigens Neoantigens are mutated peptides that are expressed by tumor cells, but not by normal tissue. As a result, they can be recognized as foreign antigens by cells of the immune system — making them promising targets for personalized cancer immunotherapies such as vaccines [...]
13 Mar, 2018
ImmunogenomicsID™
ImmunogenomicsID™ Comprehensive immunogenomic characterization ImmunogenomicsID™, the latest analytics component of the ACE ImmunoID platform, summarizes critical areas of tumor biology such as the antigen processing machinery (APM), human leukocyte antigens (HLA), checkpoint modulation, and tumor escape. ImmunogenomicsID combines exome and transcriptome sequencing data from a paired tumor and normal [...]